Growth response to recombinant human growth hormone of mammalian cell origin in prepubertal growth hormone-deficient children during the first two years of treatment.

Growth response in prepubertal children with idiopathic growth hormone deficiency during the first year of treatment with human growth hormone. Analysis of the Kabi International Growth Study.

Immunogenicity of a mammalian cell-derived recombinant human growth hormone preparation during long-term treatment.

Predicting the response of growth hormone-deficient children to long term treatment with human growth hormone.

Growth response in the first year of growth hormone treatment in prepubertal children with organic growth hormone deficiency: a comparison with idiopathic growth hormone deficiency. The Executive Scientific Committee of the Kabi International Growth Study.

Treatment of children with Down syndrome and growth retardation with recombinant human growth hormone.

Ten years of biosimilar recombinant human growth hormone in Europe.

Long-term response to human growth hormone in 36 children with idiopathic growth hormone deficiency.

Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children.

Dose dependence of growth response to human growth hormone in growth hormone deficiency.

Growth-hormone response to haemodialysis in children.

Relationship between initial treatment effect of recombinant human growth hormone and exon 3 polymorphism of growth hormone receptor in Chinese children with growth hormone deficiency.

Facial growth response to human growth hormone in hypopituitary dwarfs.

Comparison between short- and long-term insulin-like growth factor response to recombinant human growth hormone.

Growth hormone treatment in non-growth hormone-deficient children.

Slipped capital femoral epiphysis during treatment with recombinant growth hormone for isolated, partial growth hormone deficiency.

Growth hormone release during sleep in growth-retarded children with normal response to pharmacological tests.

Spanish multicenter clinical trial of recombinant growth hormone produced in mammalian cells for treatment of growth failure due to idiopathic growth hormone deficiency. Spanish Multicenter Study Group.

An examination of the effects of different doses of recombinant human growth hormone on children with growth hormone deficiency.

Constitutional delay influences the auxological response to growth hormone treatment in children with short stature and growth hormone sufficiency.

Pituitary size and response of growth hormone deficient children to growth hormone therapy.

Five-year response to growth hormone in children with Noonan syndrome and growth hormone deficiency.

Reference curve for the first-year growth response to growth hormone treatment in prepubertal children with idiopathic growth hormone deficiency: validation of the KIGS first-year growth response curve using the Belgian Register for the Study of Growth and Puberty Problems.

Recombinant Human Growth Hormone: HIV-Related Lipodystrophy.

Multicenter clinical trial to evaluate the therapeutic use of recombinant growth hormone from mammalian cells in the treatment of growth hormone neurosecretory dysfunction.

Suggest Documents

Growth response in prepubertal children with idiopathic growth hormone deficiency during the first year of treatment with human growth hormone. Analysis of the Kabi International Growth Study.

Immunogenicity of a mammalian cell-derived recombinant human growth hormone preparation during long-term treatment.

Predicting the response of growth hormone-deficient children to long term treatment with human growth hormone.

Growth response in the first year of growth hormone treatment in prepubertal children with organic growth hormone deficiency: a comparison with idiopathic growth hormone deficiency. The Executive Scientific Committee of the Kabi International Growth Study.

Treatment of children with Down syndrome and growth retardation with recombinant human growth hormone.

Ten years of biosimilar recombinant human growth hormone in Europe.

Long-term response to human growth hormone in 36 children with idiopathic growth hormone deficiency.

Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children.

Dose dependence of growth response to human growth hormone in growth hormone deficiency.

Growth-hormone response to haemodialysis in children.

Relationship between initial treatment effect of recombinant human growth hormone and exon 3 polymorphism of growth hormone receptor in Chinese children with growth hormone deficiency.

Facial growth response to human growth hormone in hypopituitary dwarfs.

Comparison between short- and long-term insulin-like growth factor response to recombinant human growth hormone.

Growth hormone treatment in non-growth hormone-deficient children.

Slipped capital femoral epiphysis during treatment with recombinant growth hormone for isolated, partial growth hormone deficiency.

Growth hormone release during sleep in growth-retarded children with normal response to pharmacological tests.

Spanish multicenter clinical trial of recombinant growth hormone produced in mammalian cells for treatment of growth failure due to idiopathic growth hormone deficiency. Spanish Multicenter Study Group.

An examination of the effects of different doses of recombinant human growth hormone on children with growth hormone deficiency.

Constitutional delay influences the auxological response to growth hormone treatment in children with short stature and growth hormone sufficiency.

Pituitary size and response of growth hormone deficient children to growth hormone therapy.

Five-year response to growth hormone in children with Noonan syndrome and growth hormone deficiency.

Reference curve for the first-year growth response to growth hormone treatment in prepubertal children with idiopathic growth hormone deficiency: validation of the KIGS first-year growth response curve using the Belgian Register for the Study of Growth and Puberty Problems.

Recombinant Human Growth Hormone: HIV-Related Lipodystrophy.

Multicenter clinical trial to evaluate the therapeutic use of recombinant growth hormone from mammalian cells in the treatment of growth hormone neurosecretory dysfunction.

Growth response to recombinant human growth hormone of mammalian cell origin in prepubertal growth hormone-deficient children during the first two years of treatment.

Recommend Documents

Follow Us